Loading...

Neurotech International

ASX:NTI
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NTI
ASX
A$3M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Neurotech International Limited engages in the research, design, development, and manufacture of medical devices in Australia. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
  • Neurotech International has significant price volatility in the past 3 months.
NTI Share Price and Events
7 Day Returns
228.6%
ASX:NTI
4.1%
AU Medical Equipment
-0%
AU Market
1 Year Returns
-88.5%
ASX:NTI
-3.3%
AU Medical Equipment
4.9%
AU Market
NTI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Neurotech International (NTI) 228.6% 4.5% - -88.5% - -
AU Medical Equipment 4.1% 0.9% 0.8% -3.3% 38.7% 103.7%
AU Market -0% 1.5% 6.5% 4.9% 18.2% 4.8%
1 Year Return vs Industry and Market
  • NTI underperformed the Medical Equipment industry which returned -3.3% over the past year.
  • NTI underperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
NTI
Industry
5yr Volatility vs Market

Value

 Is Neurotech International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Neurotech International. This is due to cash flow or dividend data being unavailable. The share price is A$0.023.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Neurotech International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Neurotech International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:NTI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.04
ASX:NTI Share Price ** ASX (2019-04-18) in AUD A$0.02
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 545 Publicly-Listed Companies 16.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Neurotech International.

ASX:NTI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:NTI Share Price ÷ EPS (both in AUD)

= 0.02 ÷ -0.04

-0.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neurotech International is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Neurotech International is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Neurotech International's expected growth come at a high price?
Raw Data
ASX:NTI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Neurotech International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Neurotech International's assets?
Raw Data
ASX:NTI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.02
ASX:NTI Share Price * ASX (2019-04-18) in AUD A$0.02
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.72x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:NTI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:NTI Share Price ÷ Book Value per Share (both in AUD)

= 0.02 ÷ 0.02

0.98x

* Primary Listing of Neurotech International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neurotech International is good value based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Neurotech International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Neurotech International has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Neurotech International expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neurotech International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Neurotech International expected to grow at an attractive rate?
  • Unable to compare Neurotech International's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Neurotech International's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Neurotech International's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:NTI Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.5%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:NTI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:NTI Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -3 -4
2018-09-30 0 -3 -4
2018-06-30 0 -3 -4
2018-03-31 0 -3 -4
2017-12-31 0 -3 -4
2017-09-30 0 -3 -4
2017-06-30 0 -3 -4
2016-12-31 0 -3 -4
2016-09-30 0 -2 -4
2016-06-30 0 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Neurotech International is high growth as no earnings estimate data is available.
  • Unable to determine if Neurotech International is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:NTI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Neurotech International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:NTI Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.04
2018-09-30 -0.04
2018-06-30 -0.04
2018-03-31 -0.04
2017-12-31 -0.04
2017-09-30 -0.05
2017-06-30 -0.05
2016-12-31 -0.09
2016-09-30 -0.08
2016-06-30 -0.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Neurotech International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of NTI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Neurotech International's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Neurotech International's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Neurotech International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Neurotech International has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Neurotech International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Neurotech International's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Neurotech International does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Neurotech International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Neurotech International's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Neurotech International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Neurotech International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:NTI Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.19 -3.84 2.53 0.30
2018-09-30 0.11 -3.91 2.57 0.29
2018-06-30 0.03 -3.99 2.60 0.29
2018-03-31 0.05 -3.93 2.57 0.28
2017-12-31 0.08 -3.86 2.54 0.26
2017-09-30 0.08 -3.95 2.71 0.25
2017-06-30 0.09 -4.03 2.89 0.24
2016-12-31 0.17 -4.29 3.43 0.06
2016-09-30 0.19 -3.54 2.80 0.05
2016-06-30 0.21 -2.79 2.18 0.03
2015-12-31 0.22 -0.84 0.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Neurotech International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Neurotech International has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Neurotech International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Neurotech International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Neurotech International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Neurotech International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Neurotech International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Neurotech International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Neurotech International has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Neurotech International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 28.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Neurotech International Company Filings, last reported 3 months ago.

ASX:NTI Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2.56 0.03 0.45
2018-09-30 2.56 0.03 0.45
2018-06-30 4.23 0.03 2.21
2018-03-31 4.23 0.03 2.21
2017-12-31 6.20 0.36 4.53
2017-09-30 6.20 0.36 4.53
2017-06-30 4.30 0.37 2.64
2016-12-31 6.03 0.47 4.58
2016-09-30 6.03 0.47 4.58
2016-06-30 1.47 0.95 1.01
2015-12-31 1.29 1.78 1.88
  • Neurotech International's level of debt (1.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Neurotech International's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Neurotech International has less than a year of cash runway based on current free cash flow.
  • Neurotech International has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.3% each year.
X
Financial health checks
We assess Neurotech International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Neurotech International has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Neurotech International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Neurotech International dividends.
If you bought A$2,000 of Neurotech International shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Neurotech International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Neurotech International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:NTI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Neurotech International has not reported any payouts.
  • Unable to verify if Neurotech International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Neurotech International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Neurotech International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Neurotech International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Neurotech International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Neurotech International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Neurotech International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter James Griffiths
COMPENSATION A$106,126
AGE 54
TENURE AS CEO 0.4 years
CEO Bio

Mr. Peter James Lawrence Griffiths has been the Chief Executive Officer and Managing Director at Neurotech International Limited since November 26, 2018. Mr. Griffiths a Senior Advisor at Bridge Growth Partners, LLC since January, 2018. He also served as a Member of Technology Advisory Board at Neurotech International Limited since joining on January 21, 2015. Mr. Griffiths serves as Deputy Chairman at Neurotech International Limited and it’s a Director since May 2016. He has been a Director of Accedian Networks Inc. since June 06, 2017. He has been a Director of Martin Dawes Analytics since September 16, 2013, Lavastorm Analytics AB since September 2013 and Lavastorm Analytics, Inc. since September 16, 2013. He serves on the board of BackOffice Associates. He serves on the Board of Trustees of the Anita Borg Institute. He served as Executive Vice President and Group Executive of Enterprise Solutions & Technology Group at CA, Inc. (alternate name CA Technologies) from February 2012 to May 2014. Mr. Griffiths managed a broad portfolio of IT management and security products for enterprise and growth markets. As Executive Vice President and Group Executive at CA Technologies, he delivered business growth through new product development and a targeted M&A strategy and also led the transition to Mobile, Cloud and DevOps with the CA Technologies Innovation Center. He served as an Executive Vice President of Technology and Development Group at CA Technologies since May 2011. In his role at CA Technologies, he was responsible for investment and strategy across its broad portfolio of products and solutions for enterprise and growth markets, including leading five business units which drove CA Technologies’ leadership in IT Management Cloud, DevOps and Security. He joined CA Technologies from IBM, where for the past two years he served as a Vice President of Worldwide Research and Development Business, Analytics and Applications. At IBM, he also served as a Vice President of Products, IBM Cognos Software. He served as a Senior Vice President of Products at Cognos Espana. In his role at IBM, where he served as Vice President of WW Business Analytics and Applications Development where he was responsible for building the Business Analytics division within IBM Software Group, including the acquisition and integration of SPSS, Clarity and OpenPages. Peter has also held positions in management consulting and in the financial services industry – including as design consultant at Apple Computer, Vodafone and Fidessa. Mr. Griffiths has more than 20 years of senior level leadership experience in software and data analytics with CA Technologies, IBM and Cognos, as well as experience in management consulting and financial services. He served as a Senior Vice President of Products for Cognos ULC since April 2002. He served as Senior Vice President of Research and Development at Cognos ULC from February 2002 to April 2002; Vice President of Research and Development from January 2001 to February 2002 and its Vice President of Decision Platform from June 2000 to January 2001. Prior to joining Cognos in 1998, he co-founded Relational Matters and served as its Chief Executive Officer. Mr. Griffiths earned a Bachelor of Science degree in Electronic Engineering with 1st Class Honors from Brighton University in England.

CEO Compensation
  • Peter James's compensation has increased whilst company is loss making.
  • Peter James's remuneration is lower than average for companies of similar size in Australia.
Management Team

Peter James Griffiths

TITLE
Deputy Chairman
COMPENSATION
A$106K
AGE
54
TENURE
0.4 yrs

Emanuela Russo

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board
TENURE
0.5 yrs

Fleur Hudson

TITLE
Company Secretary
Board of Directors

Peter James Griffiths

TITLE
Deputy Chairman
COMPENSATION
A$106K
AGE
54

Emanuela Russo

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board

David Cantor

TITLE
Chairman of Scientific Advisory Board & Non-Executive Director

Tanju Surmeli

TITLE
Member of Scientific Advisory Board
TENURE
0.5 yrs

Evian Gordon

TITLE
Member of Scientific Advisory Board
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
28. Feb 19 Buy Pyxis Holdings Pty Ltd Company 25. Feb 19 25. Feb 19 3,749,999 A$0.03 A$112,500
12. Nov 18 Sell Adrian Trevisan Individual 09. Nov 18 09. Nov 18 -190,832 A$0.07 A$-12,658
19. Aug 18 Sell Adrian Trevisan Individual 08. Aug 18 16. Aug 18 -243,807 A$0.18 A$-38,162
27. Jun 18 Buy SG Hiscock & Company Ltd. Company 29. Jan 18 25. Jun 18 2,500,000 A$0.22 A$534,159
X
Management checks
We assess Neurotech International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Neurotech International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does Neurotech International Limited (ASX:NTI) Have A Particularly Volatile Share Price?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Could The Neurotech International Limited (ASX:NTI) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Neurotech International Limited (ASX:NTI) have power over the company. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … With a market capitalization of AU$5.3m, Neurotech International is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

What Kind Of Shareholders Own Neurotech International Limited (ASX:NTI)?

Every investor in Neurotech International Limited (ASX:NTI) should be aware of the most powerful shareholder groups. … Neurotech International is a smaller company with a market capitalization of AU$11m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

What does Neurotech International Limited's (ASX:NTI) Balance Sheet Tell Us About Its Future?

Investors are always looking for growth in small-cap stocks like Neurotech International Limited (ASX:NTI), with a market cap of AU$13.08m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Is Neurotech International Limited's (ASX:NTI) Balance Sheet A Threat To Its Future?

With this debt payback, the current cash and short-term investment levels stands at AU$2.64M for investing into the business. … Moving onto cash from operations, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look. … Investors' risk associated with debt is virtually non-existent with NTI, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: Although NTI’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.

Simply Wall St -

How Did Neurotech International Limited's (ASX:NTI) Earnings Growth Stack Up Against The Industry?

Below, I will assess Neurotech International Limited's (ASX:NTI) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … View our latest analysis for Neurotech International Did NTI's recent earnings growth beat the long-term trend and the industry? … For Neurotech International, its latest earnings (trailing twelve month) is -AU$3.86M, which, against the prior year's figure, has become less negative.

Simply Wall St -

How Should Investors React To Neurotech International Limited's (ASX:NTI) CEO Pay?

Recently, NTI delivered negative earnings of -AU$3.86M. … As profits are moving up and up, CEO pay should represent Storf's value creation for shareholders. … Normally I would look at market cap and earnings as a proxy for performance, however, NTI's negative earnings reduces the effectiveness of this method.

Simply Wall St -

What Does Neurotech International Limited's (ASX:NTI) Ownership Structure Look Like?

See our latest analysis for Neurotech International ASX:NTI Ownership_summary Feb 26th 18 Institutional Ownership Institutional investors transact in large blocks which can influence the momentum of stock prices, at least in the short-term, especially when there is a low level of public shares available on the market to trade. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: With a low level of institutional ownership, investors in NTI need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

When Will Neurotech International Limited (ASX:NTI) Run Out Of Money?

Looking at Neurotech International’s latest financial data, I will gauge when the company may run out of cash and need to raise more money. … ASX:NTI Income Statement Feb 15th 18 When will Neurotech International need to raise more cash? … Not surprisingly, if Neurotech International continues to ramp up expenditure at this rate for the upcoming year, it’ll likely need to come to market within the next few months, given the its current level of cash reserves.

Simply Wall St -

Is Neurotech International Limited's (ASX:NTI) Balance Sheet Strong Enough To Weather A Storm?

NTI has shrunken its total debt levels in the last twelve months, from AU$945.61K to AU$374.80K – this includes both the current and long-term debt. … Moving onto cash from operations, its operating cash flow is not yet significant enough to calculate a meaningful cash-to-debt ratio, indicating that operational efficiency is something we’d need to take a look at. … Investors' risk associated with debt is virtually non-existent with NTI, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: Although NTI’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.

Simply Wall St -

Company Info

Description

Neurotech International Limited engages in the research, design, development, and manufacture of medical devices in Australia. Its product is Mente Autism, a portable electroencephalogram medical device that uses neurofeedback to help relax the minds of children with autism spectrum disorder. The company focuses on developing neuro-stimulation and neuro-diagnostic solutions that enable medical practitioners to monitor and play an active role in home-based therapies. It also engages in executing medical research projects and developing technological devices; and publishing, registering, and maintaining intellectual property. The company also focuses on establishing new markets in the United Kingdom, France, and Spain. Neurotech International Limited was incorporated in 2016 and is based in Perth, Australia.

Details
Name: Neurotech International Limited
NTI
Exchange: ASX
Founded: 2016
A$3,122,108
135,743,869
Website: http://www.neurotechinternational.com
Address: Neurotech International Limited
191 St Georges Terrace,
Level 14,
Perth,
Western Australia, 6000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX NTI Ordinary Shares Australian Securities Exchange AU AUD 04. Nov 2016
OTCPK NTIL.F Ordinary Shares Pink Sheets LLC US USD 04. Nov 2016
CHIA NTI Ordinary Shares Chi-X Australia AU AUD 04. Nov 2016
Number of employees
Current staff
Staff numbers
0
Neurotech International employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 10:35
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.